Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06562296 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers
A Phase 4 study of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Cellution Biologics.
- Active
- Registry status
- Phase 4
- Development phase
- 292
- Enrollment target
- 4
- Study locations
NCT06562296: Active Phase 4 study of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Cellution Biologics.
NCT06562296 is a Phase 4 study of Diabetic Foot Ulcer and Venous Leg Ulcer that is active but no longer recruiting, run by Cellution Biologics. The registered enrollment target is 292 participants, above the 251-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (16% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06562296, a Phase 4 study of Diabetic Foot Ulcer and Venous Leg Ulcer, is active but no longer recruiting, sponsored by Cellution Biologics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 292 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine how well multiple CAMPs (Cellular, Acellular and Matrix-Like Products) and Standard of Care work when compared to Standard of Care alone in achieving complete closure of diabetic foot and venous leg ulcers.
Primary Outcome
The percentage of DFU and VLU target ulcers achieving complete wound closure. Closure is defined by 100% re-epithelialization of the ulcer surface without detectable exudate.
Conditions Studied
Interventions
- OTHER Amnion-Intermediate-Chorion
- PROCEDURE Standard of Care
- OTHER Amnion-Chorion-Amnion
Study Locations (4)
Florida
- Symphony Research - Jacksonville
Ohio
- Sure Step Foot & Ankle - Cincinnati
Texas
- RGV Wound Care Group - Weslaco
Wisconsin
- Family Foot & Ankle - Kenosha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-12-25 |
| Phase | Phase 4 |
What the registry record for NCT06562296 still lists
NCT06562296 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, above the 251-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (16% higher).
The record links to 2 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 3 interventions - of which Amnion-Intermediate-Chorion is the first listed.
NCT06562296 reports a single indexed study location in Florida, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT06562296 about?
NCT06562296 is a clinical study titled "Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers". The purpose of this study is to determine how well multiple CAMPs (Cellular, Acellular and Matrix-Like Products) and Standard of Care work when compared to Standard of Care alone in achieving complete closure of diabetic foot and venous leg ulcers.
What is the current status of trial NCT06562296?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 292 participants. The study started on 2024-10-14. Estimated completion is 2025-12-25.
What conditions does trial NCT06562296 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer, Venous Leg Ulcer.
What interventions are being tested in trial NCT06562296?
The interventions under investigation include: Amnion-Intermediate-Chorion (OTHER), Standard of Care (PROCEDURE), Amnion-Chorion-Amnion (OTHER).
Who is sponsoring clinical trial NCT06562296?
This trial is sponsored by Cellution Biologics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06562296 being conducted?
This trial has 4 study locations across Florida, Ohio, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06562296's enrollment target sits among peer trials
292 12th of 67 higher than 56 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
RECRUITING · Phase 4
-
Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC)
RECRUITING · Phase 4
-
A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers
RECRUITING · Phase 4
-
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
RECRUITING · Phase 4
-
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
RECRUITING · Phase 4
-
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI